Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FR-S is a chemically sulfated derivative of a (1→6)-(1→3)-β-D-glucan isolated from the fruiting bodies of the mushroom *Agaricus subrufescens* (also known as *Agaricus brasiliensis*). It is being investigated as a broad-spectrum antiviral agent and an inhibitor of viral pathogenesis. FR-S has demonstrated significant in vitro and in vivo efficacy against flaviviruses, including Dengue virus (DENV) and Zika virus (ZIKV), by inhibiting viral entry and preventing nonstructural protein 1 (NS1)-mediated endothelial hyperpermeability and vascular leak. Additionally, FR-S has shown activity against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) by blocking viral adsorption and penetration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FR-S.